Background: Extracts from Viscum album (VA-E) have been shown to induce apoptosis and
immunoactivation. To exclude possible B-CLL propagating effects, the in vitro reactions of …

Background: In a prospective observational study, the impact of two different dose regimes
of a commercially available fermented Viscum album L. extract (VA-E, Iscador®) on the …

Background Extracts from Viscum album L.(VAL), which are one of the most widely used
alternative cancer therapies in Europe, have been recognised to induce apoptosis. A …

Abstract Background: Viscum album (VA) Qu FrF preparation consists of an aqueous extract
of Viscum album, the European mistletoe. It has cytotoxic and immunomodulatory properties …

Background: In a previous study a decline of T-lymphocyte function was observed within a 6-
month period of Viscum album extract (VA-E) application which did not occur in those …

Viscum albumL.(mistletoe) extracts are widely used in adjuvant cancer therapy. In contrast to
purified components, such as mistletoe lectins and viscotoxins, whole plant extracts of …

Viscum album L.(VAL) is a phytopreparation used in adjuvant cancer therapy with both
immunostimulatory and DNA stabilizing properties at low drug concentrations and …

Background: CLL is a malignant monoclonal disorder of the lymphatic system. The VA-E
treatment modulates the humoral and cellular immune system. A case report on B-cell …

The killing capacity of extracts from Viscum album L., widely used as an adjuvant in
complementary cancer therapy, is dependent on the content of toxic proteins, especially the …

Extracts from European mistletoe or Viscum album L. have been reported to exert cytotoxic
and immunomodulatory effects in vitro and in vivo. The mechanism of this anti-tumoral …